» Articles » PMID: 15840634

The Impact of China's Retail Drug Price Control Policy on Hospital Expenditures: a Case Study in Two Shandong Hospitals

Overview
Date 2005 Apr 21
PMID 15840634
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In China, 44.4% of total health expenditures in 2001 were for pharmaceuticals. Containment of pharmaceutical expenditures is a top priority for policy intervention. Control of drug retail prices was adopted by the Chinese government for this purpose. This study aims to examine the impact of this policy on the containment of hospital drug expenditures, and to analyze contributing factors. This is a retrospective pre/post-reform case study in two public hospitals. Financial records were reviewed to analyze changes in drug expenditures for all patients. A tracer condition, cerebral infarction, was selected for in-depth examination of changes in prices, utilization, expenditures and rationality of drugs. In the two hospitals, a total of 104 and 109 cerebral infarction cases, hospitalized respectively before and after the reform, were selected. Prescribed daily dose (PDD) was used for measuring drug utilization, and the contribution of price and utilization to changes in drug expenditures were decomposed. Rationality of drug use post-reform was reviewed based on published literature. Drug expenditures for all patients still increased rapidly in the two hospitals after implementation of the pricing policy. In the provincial hospital, drug expenditures per patient for cerebral infarction cases declined, but not significantly. This was mainly attributable to reduced utilization. In the municipal hospital, drug expenditure per patient increased by 50.1% after the reform, mainly due to greater drug utilization. Three to five fold higher drug expenditure per inpatient day in the provincial hospital was due to use of more expensive drugs. Of the top 15 drugs for treating cerebral infarction cases after the reform, 19.5% and 46.5% of the expenditures, in the provincial and municipal hospitals, respectively, were spent on drugs with prices set by the government. A large proportion of expenditures for the top 15 drugs, at least 65% and 41% in the provincial and municipal hospitals, respectively, was spent on allopathic drugs without an adequate evidence base of safety and efficacy supporting use for cerebral infarction. Control of retail prices, implemented in isolation, was not effective in containing hospital drug expenditures in these two Chinese hospitals. Utilization, more than price, determined drug expenditures. Improvement of rational use of drugs and correcting the present incentive structure for hospitals and drug prescribers may be important additional strategies for achieving containment of drug expenditures.

Citing Articles

The impacts of public hospital comprehensive reform policies on hospital medicine cost, revenues and healthcare expenditures 2014-2019: An analysis of 103 tertiary public hospitals in China.

Pan L, Xiao K, Zhu H, Luo L Front Health Serv. 2023; 3:1079370.

PMID: 36926494 PMC: 10012765. DOI: 10.3389/frhs.2023.1079370.


Evaluating the impact of price regulation (Drug Price Control Order 2013) on antibiotic sales in India: a quasi-experimental analysis, 2008-2018.

Selvaraj S, Hasan Farooqui H, Mehta A, Mathur M J Pharm Policy Pract. 2022; 15(1):68.

PMID: 36273222 PMC: 9587621. DOI: 10.1186/s40545-022-00466-4.


Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China.

Li Z, Liu C, Zuo K, Liu J, Tang Y Front Pharmacol. 2021; 12:741671.

PMID: 34721029 PMC: 8552023. DOI: 10.3389/fphar.2021.741671.


The impact of pharmacist oriented mode on risk control in a Chinese centralized intravenous admixture service centre.

Chen H, Guo Y, Wei H, Chen X Sci Rep. 2021; 11(1):5445.

PMID: 33686207 PMC: 7940617. DOI: 10.1038/s41598-021-85077-w.


The Effects of County Public Hospital Reform on the Consumption and Costs of Antibiotics: Evidence from a Quasinatural Experiment in Jiangsu, China.

Wang Y, Zhu Y, Liu X, Xu X, Fang W, Li X Biomed Res Int. 2020; 2020:9262170.

PMID: 33145360 PMC: 7599416. DOI: 10.1155/2020/9262170.